News | January 24, 2025
Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
This certification will open new markets for the Kwality Pharma
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
In 2023, Endox had revenues of approximately SEK 65 million
The scheme is fully digitized and covers approximately 45% of India's population
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
The site’s GMP Certification has been successfully renewed
The transaction is part of a broader agreement with Bureau Veritas covering its worldwide food laboratory testing activities
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
Subscribe To Our Newsletter & Stay Updated
